Sanara MedTech Inc. (SMTI)
USD 31.79
(-6.47%)
USD 31.79
(-6.47%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -289.09 Thousand USD | 61.04% |
| 2022 | -11.85 Million USD | -38.46% |
| 2021 | -7.22 Million USD | -57.42% |
| 2020 | -4.02 Million USD | -87.94% |
| 2019 | -2.6 Million USD | -498.73% |
| 2018 | -417.97 Thousand USD | -286.88% |
| 2017 | 538.77 Thousand USD | 205.76% |
| 2016 | -180.37 Thousand USD | 76.66% |
| 2015 | -1.1 Million USD | 54.89% |
| 2014 | -1.92 Million USD | 30.27% |
| 2013 | -2.3 Million USD | 44.58% |
| 2012 | -469.76 Thousand USD | -390.58% |
| 2011 | -4.54 Million USD | 55.96% |
| 2010 | -3.82 Million USD | -40.95% |
| 2009 | -2.41 Million USD | 2.31% |
| 2008 | -1.74 Million USD | -352.41% |
| 2007 | -385.65 Thousand USD | 17.26% |
| 2006 | -466.09 Thousand USD | 46.97% |
| 2005 | -724.6 Thousand USD | -217.52% |
| 2004 | -1.65 Million USD | 0.0% |
| 2001 | -1.38 Million USD | -45.08% |
| 2000 | -823.51 Thousand USD | -24.54% |
| 1999 | -772.78 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -491.96 Thousand USD | 60.75% |
| 2024 Q2 | -1.79 Million USD | -317.41% |
| 2023 Q3 | -590.73 Thousand USD | 58.49% |
| 2023 Q4 | -1.08 Million USD | -83.87% |
| 2023 FY | - USD | 61.04% |
| 2023 Q2 | -1.42 Million USD | -59.86% |
| 2023 Q1 | -890.13 Thousand USD | 72.51% |
| 2022 Q1 | -2.95 Million USD | 11.97% |
| 2022 Q2 | -2.78 Million USD | 5.8% |
| 2022 Q4 | -3.23 Million USD | -48.48% |
| 2022 Q3 | -2.18 Million USD | 21.63% |
| 2022 FY | - USD | -38.46% |
| 2021 Q2 | -1.1 Million USD | -1.2% |
| 2021 FY | - USD | -57.42% |
| 2021 Q3 | -1.84 Million USD | -66.79% |
| 2021 Q4 | -3.35 Million USD | -82.04% |
| 2021 Q1 | -1.09 Million USD | -41.78% |
| 2020 Q3 | -1.12 Million USD | -6.69% |
| 2020 Q2 | -1.05 Million USD | 39.73% |
| 2020 Q4 | -770.24 Thousand USD | 31.52% |
| 2020 FY | - USD | -87.94% |
| 2020 Q1 | -1.74 Million USD | -29.07% |
| 2019 Q2 | -300.44 Thousand USD | -96.62% |
| 2019 FY | - USD | -498.73% |
| 2019 Q4 | -1.35 Million USD | -95.99% |
| 2019 Q3 | -691.45 Thousand USD | -130.15% |
| 2019 Q1 | -152.8 Thousand USD | 65.85% |
| 2018 Q3 | -122.73 Thousand USD | -319.16% |
| 2018 Q2 | 56 Thousand USD | -42.04% |
| 2018 Q1 | 96.62 Thousand USD | 1459.36% |
| 2018 FY | - USD | -286.88% |
| 2018 Q4 | -447.43 Thousand USD | -264.57% |
| 2017 Q4 | -7108.00 USD | -156.3% |
| 2017 Q1 | 78.37 Thousand USD | -73.15% |
| 2017 Q3 | 12.62 Thousand USD | -90.95% |
| 2017 Q2 | 139.53 Thousand USD | 78.04% |
| 2017 FY | - USD | 205.76% |
| 2016 Q3 | 231.43 Thousand USD | 126.04% |
| 2016 Q1 | 154.02 Thousand USD | 140.67% |
| 2016 Q2 | -888.63 Thousand USD | -676.96% |
| 2016 FY | - USD | 76.66% |
| 2016 Q4 | 291.93 Thousand USD | 26.14% |
| 2015 Q2 | -328.29 Thousand USD | -304.59% |
| 2015 Q3 | -116.79 Thousand USD | 64.42% |
| 2015 FY | - USD | 54.89% |
| 2015 Q1 | -81.14 Thousand USD | 65.51% |
| 2015 Q4 | -378.69 Thousand USD | -224.23% |
| 2014 Q4 | -235.27 Thousand USD | 62.85% |
| 2014 Q3 | -633.32 Thousand USD | 14.15% |
| 2014 Q2 | -737.71 Thousand USD | -84.58% |
| 2014 Q1 | -399.66 Thousand USD | 87.99% |
| 2014 FY | - USD | 30.27% |
| 2013 Q3 | 942.8 Thousand USD | 458.69% |
| 2013 Q2 | -262.84 Thousand USD | 32.66% |
| 2013 Q1 | -390.33 Thousand USD | 86.86% |
| 2013 FY | - USD | 44.58% |
| 2013 Q4 | -3.32 Million USD | -453.11% |
| 2012 FY | - USD | -390.58% |
| 2012 Q4 | -2.97 Million USD | -76.5% |
| 2012 Q3 | -1.68 Million USD | -344.62% |
| 2012 Q2 | -378.66 Thousand USD | -141.12% |
| 2012 Q1 | -157.04 Thousand USD | -183.7% |
| 2011 Q1 | -167.5 Thousand USD | 80.51% |
| 2011 FY | - USD | 55.96% |
| 2011 Q4 | 187.63 Thousand USD | 133.67% |
| 2011 Q3 | -557.21 Thousand USD | 1.23% |
| 2011 Q2 | -564.16 Thousand USD | -236.8% |
| 2010 FY | - USD | -40.95% |
| 2010 Q1 | -307.21 Thousand USD | 60.62% |
| 2010 Q2 | -457.34 Thousand USD | -48.87% |
| 2010 Q3 | -768.42 Thousand USD | -68.02% |
| 2010 Q4 | -859.51 Thousand USD | -11.85% |
| 2009 Q2 | -247.59 Thousand USD | 46.88% |
| 2009 Q3 | -229.77 Thousand USD | 7.2% |
| 2009 Q1 | -466.14 Thousand USD | 42.85% |
| 2009 Q4 | -780.14 Thousand USD | -239.52% |
| 2009 FY | - USD | 2.31% |
| 2008 Q4 | -815.69 Thousand USD | -127.44% |
| 2008 Q2 | -214.93 Thousand USD | 39.54% |
| 2008 Q1 | -355.48 Thousand USD | -92.14% |
| 2008 FY | - USD | -352.41% |
| 2008 Q3 | -358.63 Thousand USD | -66.86% |
| 2007 Q2 | 29.65 Thousand USD | 120.74% |
| 2007 FY | - USD | 17.26% |
| 2007 Q4 | -185.01 Thousand USD | -111.9% |
| 2007 Q3 | -87.31 Thousand USD | -394.38% |
| 2007 Q1 | -142.99 Thousand USD | -2.58% |
| 2006 Q2 | -83.35 Thousand USD | 12.72% |
| 2006 Q1 | -95.5 Thousand USD | 67.9% |
| 2006 Q3 | -66.96 Thousand USD | 19.66% |
| 2006 Q4 | -139.39 Thousand USD | -108.17% |
| 2006 FY | - USD | 46.97% |
| 2005 FY | - USD | -217.52% |
| 2005 Q4 | -297.47 Thousand USD | -200.77% |
| 2005 Q2 | -81.84 Thousand USD | 48.91% |
| 2005 Q1 | -160.19 Thousand USD | -1308.35% |
| 2005 Q3 | -98.9 Thousand USD | -20.84% |
| 2004 Q4 | 13.25 Thousand USD | 110.94% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | -121.13 Thousand USD | -22.29% |
| 2004 Q2 | -99.06 Thousand USD | -42.78% |
| 2004 Q1 | -69.38 Thousand USD | 0.0% |
| 2002 Q1 | -267.74 Thousand USD | 74.32% |
| 2001 Q4 | -1.04 Million USD | -3199.23% |
| 2001 Q1 | 19.49 Thousand USD | 103.96% |
| 2001 FY | - USD | -45.08% |
| 2001 Q3 | -264.06 Thousand USD | 68.0% |
| 2001 Q2 | -98.75 Thousand USD | -606.62% |
| 2000 FY | - USD | -24.54% |
| 2000 Q2 | -306 Thousand USD | -45167.31% |
| 2000 Q3 | -174.93 Thousand USD | 43.13% |
| 2000 Q1 | -676.00 USD | 0.0% |
| 2000 Q4 | -491.85 Thousand USD | -182.61% |
| 1999 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -45.63 Million USD | 99.366% |
| AngioDynamics, Inc. | -14.29 Million USD | 97.977% |
| AtriCure, Inc. | -8.1 Million USD | 96.435% |
| Avinger, Inc. | -16.34 Million USD | 98.231% |
| Azenta, Inc. | 55.15 Million USD | 100.524% |
| BioLife Solutions, Inc. | -45.23 Million USD | 99.361% |
| The Cooper Companies, Inc. | 882.8 Million USD | 100.033% |
| Daxor Corporation | 329.74 Thousand USD | 187.674% |
| Ekso Bionics Holdings, Inc. | -13.19 Million USD | 97.81% |
| Femasys Inc. | -13.16 Million USD | 97.805% |
| GlucoTrack, Inc. | -7.09 Million USD | 95.923% |
| Harvard Bioscience, Inc. | 9.49 Million USD | 103.045% |
| Hologic, Inc. | 1.29 Billion USD | 100.022% |
| ICU Medical, Inc. | 307.69 Million USD | 100.094% |
| Intuitive Surgical, Inc. | 2.39 Billion USD | 100.012% |
| KORU Medical Systems, Inc. | -9.39 Million USD | 96.924% |
| LeMaitre Vascular, Inc. | 48.99 Million USD | 100.59% |
| Innovative Eyewear, Inc. | -6.57 Million USD | 95.603% |
| Innovative Eyewear, Inc. | -6.57 Million USD | 95.603% |
| Masimo Corporation | 236.7 Million USD | 100.122% |
| Microbot Medical Inc. | -10.63 Million USD | 97.281% |
| Meihua International Medical Technologies Co., Ltd. | 15.77 Million USD | 101.833% |
| Merit Medical Systems, Inc. | 231.44 Million USD | 100.125% |
| Nephros, Inc. | -1.37 Million USD | 79.036% |
| NovoCure Limited | -175.86 Million USD | 99.836% |
| NEXGEL, Inc. | -2.73 Million USD | 89.41% |
| NEXGEL, Inc. | -2.73 Million USD | 89.41% |
| Singular Genomics Systems, Inc. | -86.49 Million USD | 99.666% |
| OraSure Technologies, Inc. | 76.15 Million USD | 100.38% |
| Pro-Dex, Inc. | 8.33 Million USD | 103.469% |
| Pulse Biosciences, Inc. | -42.36 Million USD | 99.318% |
| Predictive Oncology Inc. | -13.18 Million USD | 97.807% |
| Precision Optics Corporation, Inc. | -2.51 Million USD | 88.491% |
| QuidelOrtho Corporation | 545.6 Million USD | 100.053% |
| Repligen Corporation | 124.29 Million USD | 100.233% |
| STAAR Surgical Company | 33.22 Million USD | 100.87% |
| Sharps Technology, Inc. | -8.98 Million USD | 96.781% |
| Utah Medical Products, Inc. | 24.8 Million USD | 101.165% |
| DENTSPLY SIRONA Inc. | 232 Million USD | 100.125% |
| Jin Medical International Ltd. | 3.44 Million USD | 108.397% |